β-Adrenergic Receptor Blockade in Chronic Heart Failure
暂无分享,去创建一个
[1] J. Cohn,et al. Effect of carvedilol in severe chronic heart failure , 1996 .
[2] M. Bristow,et al. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. , 1970, The Journal of pharmacology and experimental therapeutics.
[3] M. Bristow,et al. The role of third‐generation beta‐blocking agents in chronic heart failure , 1998, Clinical cardiology.
[4] G. Newton,et al. Acute Effects of β1-Selective and Nonselective β-Adrenergic Receptor Blockade on Cardiac Sympathetic Activity in Congestive Heart Failure , 1996 .
[5] M. Bristow. Changes in myocardial and vascular receptors in heart failure. , 1993, Journal of the American College of Cardiology.
[6] M. Hetzel,et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). , 1997, Circulation.
[7] U. Borchard. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. , 1990, Clinical physiology and biochemistry.
[8] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[9] M. Bristow,et al. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. , 1997, The American journal of cardiology.
[10] L. Wilkins. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.
[11] K. Swedberg,et al. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. , 1980, British heart journal.
[12] R. Hetzer,et al. Regional Distribution of β‐Adrenoceptors in the Human Heart: Coexistence of Functional β1 and β2-Adrenoceptors in Both Atria and Ventricles in Severe Congestive Cardiomyopathy , 1986 .
[13] W. Abraham,et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.
[14] J. Port,et al. Receptor pharmacology of carvedilol in the human heart. , 1992, Journal of cardiovascular pharmacology.
[15] A. Lenarda,et al. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy , 1991 .
[16] A R Jayaweera,et al. Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy? , 1993, Circulation.
[17] J. A. Bowers,et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.
[18] C. Ng,et al. Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability. , 1995, The American journal of cardiology.
[19] P. Korner,et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.
[20] E. Varnauskas,et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.
[21] M. Bristow. Mechanism of action of beta-blocking agents in heart failure. , 1997, The American journal of cardiology.
[22] E. Braunwald,et al. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. , 1963, The American journal of medicine.
[23] D. Renlund,et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.
[24] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[25] G. Plotnick,et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.
[26] D. Richards,et al. Clinical pharmacology of labetalol. , 1979, British journal of clinical pharmacology.
[27] L. Mestroni,et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. , 1992, The Journal of clinical investigation.
[28] S. Vatner,et al. Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .
[29] R. Dixon,et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[30] E. Brendel,et al. Carvedilol increases the systemic bioavailability of oral digoxin. , 1990, British journal of clinical pharmacology.
[31] Catherine Communal,et al. Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .
[32] M. Lohse,et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Reeves,et al. β‐Blockade disappearance rate predicts β‐adrenergic hypersensitivity , 1989 .
[34] P. Grayburn,et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.
[35] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[36] R. Jones,et al. Hemodynamic Effects of Labetalol in Patients with Combined Hypertension and Left Ventricular Failure , 1988, Journal of cardiovascular pharmacology.
[37] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[38] P. Armstrong,et al. Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing. , 1977, The American journal of cardiology.
[39] E. Braunwald,et al. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.
[40] W. French,et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.
[41] D. Farber,et al. Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol , 1998 .
[42] L. Špinarová,et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. , 1997, Journal of cardiac failure.
[43] K. Adams,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.
[44] R Hetzer,et al. Clinical value of echocardiographic tissue characterization in the diagnosis of myocarditis. , 1996, European heart journal.
[45] B. Bhargava,et al. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. , 1996, Journal of cardiac failure.
[46] W. Abraham,et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.
[47] K. Chatterjee. Heart failure therapy in evolution. , 1996, Circulation.
[48] K. Swedberg,et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. , 1984, The American journal of cardiology.
[49] F. Charpentier,et al. Functional beta3-adrenoceptor in the human heart. , 1996, The Journal of clinical investigation.
[50] M. Packer. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. , 1997, The American journal of cardiology.
[51] R. Hershberger,et al. Mechanism of Action of Bucindolol in Human Ventricular Myocardium , 1990, Journal of cardiovascular pharmacology.
[52] A. Strosberg,et al. Molecular characterization of the human beta 3-adrenergic receptor. , 1989, Science.
[53] G. Dorn,et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. , 2000, Circulation.
[54] Australia.. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.
[55] A. Wood,et al. Stereoselective disposition of carvedilol is determined by CYP2D6 , 1995, Clinical pharmacology and therapeutics.
[56] M. Bristow,et al. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. , 1995, European heart journal.
[57] M. Metra,et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.
[58] G. Tucker,et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers , 1983, Clinical pharmacology and therapeutics.
[59] S. Stephen. Unwanted effects of propranolol. , 1966, The American journal of cardiology.
[60] H. Krum,et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. , 1995, Circulation.
[61] M. Böhm,et al. Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. , 1994, Circulation research.
[62] M. Bristow,et al. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. , 1985, The American journal of cardiology.
[63] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[64] G. Jennings,et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. , 1995, Journal of the American College of Cardiology.
[65] P. Grayburn,et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.
[66] M. Caron,et al. Cloning of the cDNA for the human beta 1-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[67] G. Dorn,et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .
[68] P. Vanhoutte,et al. Pharmacology of bucindolol in isolated canine vascular smooth muscle. , 1984, The Journal of pharmacology and experimental therapeutics.
[69] A. Stäblein,et al. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. , 1997, Journal of the American College of Cardiology.
[70] M. Bristow,et al. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.
[71] P. Grayburn,et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. , 1990, Circulation.
[72] M. Pfeffer,et al. Beta-adrenergic blockers and survival in heart failure. , 1996, The New England journal of medicine.
[73] R. Robson,et al. Dose Proportionality of Bisoprolol Enantiomers in Humans After Oral Administration of the Racemate , 1994, Journal of clinical pharmacology.
[74] P. Molenaar,et al. Modulation of human cardiac function through 4 β-adrenoceptor populations , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[75] R. Lefkowitz,et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[76] W. Abraham,et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. , 1999, The American journal of cardiology.
[77] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[78] G. Newton,et al. Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study. , 1999, Circulation.
[79] J. Skoularigis,et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.
[80] L. Eroǧlu,et al. A study of the relationship between serum lithium and plasma cortisol levels in manic depressive patients [letter] , 1979 .
[81] J. Port,et al. Echocardiographic and Histopathological Characterization of Young and Old Transgenic Mice Over-expressing the Human β1-Adrenergic Receptor , 1998 .
[82] R. Snyder,et al. β-adrenoceptor and cardiovascular effects of MJ 13105 (Bucindolol) in anesthetized dogs and rats , 1980 .
[83] J. Ritter,et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. , 1995, The Journal of pharmacology and experimental therapeutics.
[84] R. Quaife,et al. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. , 1996, The American journal of cardiology.
[85] K. Swedberg,et al. Carvedilol for heart failure, with care , 1996, The Lancet.
[86] I. Benjamin,et al. beta Adrenergic receptor desensitisation may serve a cardioprotective role. , 1992, Cardiovascular research.
[87] J. Port,et al. Cardiac adrenergic receptor effects of carvedilol. , 1996, European heart journal.
[88] M. Metra,et al. Comparative effects of metoprolol and carvedilol on resting and peak exercise hemodynamics and functional capacity in patients with chronic heart failure. , 1997 .
[89] R. Reneman,et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. , 1988, Journal of cardiovascular pharmacology.
[90] R. Doughty,et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease , 1997 .
[91] B. Parsons,et al. Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.
[92] R G Shanks,et al. Selective blockade of adrenoceptive beta receptors in the heart. , 1968, British journal of pharmacology and chemotherapy.
[93] M. Bristow. The adrenergic nervous system in heart failure. , 1984, The New England journal of medicine.
[94] S. Gottlieb,et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.
[95] E. Snoeck,et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects , 1997, European Journal of Clinical Pharmacology.
[96] N. Kantrowitz,et al. Beta-adrenergic function in heart muscle disease and heart failure. , 1985, Journal of molecular and cellular cardiology.
[97] D. Pimentel,et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. , 1998, Circulation.
[98] G. Tucker,et al. The Polymorphic Oxidation of β-Adrenoceptor Antagonists , 1986 .
[99] S. Jamieson,et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.
[100] R. Senior,et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. , 1997, Circulation.
[101] J. Cohn,et al. Norepinephrine infusions in congestive heart failure. , 1985, The American journal of cardiology.
[102] Daniel Levy,et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. , 1999, Circulation.
[103] D. Renlund,et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.